Side effects of Deferasirox Iron Chelation in Patients with Beta Thalassemia Major or Intermedia

OBJECTIVES: Chelating agents remain the mainstay in reducing the iron burden and extending patient survival in homozygous beta-thalassemia but adverse and toxic effects may increase with the institution and long term use of this essential therapy. This study aimed to estimate the incidence of defera...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Al-Khabori, Murtadha, Bhandari, Sunil, Al-Huneini, Mohammed, Al-Farsi, Khalil, Panjwani, Vinodh, Daar, Shahina
Natura: Artigo
Lingua:Inglês
Pubblicazione: OMJ 2013
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3628199/
https://ncbi.nlm.nih.gov/pubmed/23599881
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5001/omj.2013.31
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi